Recently published research from GlobalData, "Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023", is now available at Fast Market Research

Boston, MA -- (SBWire) -- 11/17/2014 --GlobalData has released its new PharmaPoint Drug Evaluation report, "Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023". HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third, and fourth-line metastatic.

Perjeta (pertuzumab) is the second biologic to launch in Roche/Genentech's HER2-targeted therapy portfolio, and was approved by the FDA in 2012, and by the EMA and the Japanese Ministry of Health, Labour and Welfare (MHLW) in 2013. Like Herceptin, Perjeta is a monoclonal antibody (mAb) that targets HER2; however, Perjeta's mechanism of action is slightly different: whereas Herceptin blocks the binding of ligands to HER2, Perjeta binds to the extracellular dimerization domain of HER2, inhibiting ligand-dependent dimerization of the HER receptors.

View Full Report Details and Table of Contents

Scope

- Overview of HER2-Positive Breast Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Perjeta including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Perjeta for the top eight countries from 2013 to 2023.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Reasons to Get This Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for HER2-Positive Breast Cancer

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of Perjeta performance

- Obtain sales forecast for Perjeta from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 800-844-8156

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023
- PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023
- PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023
- PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023
- Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023
- Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023
- Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023
- Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023
- Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth
- EpiCast Report: Breast Cancer - Epidemiology Forecast to 2022